+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Overview: TetraVax-DV

  • PDF Icon

    Drug Pipelines

  • 16 Pages
  • January 2018
  • Region: Global
  • Citeline
  • ID: 4462224
Drug Overview

TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development. The viral strains were formulated by the US National Institutes of Health (NIH) and have been licensed by vaccine producers in India (Biological E/Panacea Biotec), Brazil (Butantan Institute), and Vietnam (Vabiotech). Merck & Co has also in-licensed the vaccine from the NIH in order to investigate the potential of a heterologous prime-boost strategy with its own in-house vaccine, V180 (adjuvanted, tetravalent DEN-80E subunit vaccine).

TetraVax-DV has emerged as a potential best-in-class live-attenuated vaccine based on Phase I studies, which showed impressive rates of tetravalent seroconversion after a single dose of the TV-003 and TV-005 formulations. The author expects that the vaccine's low production costs and anticipated lower price compared to the other tetravalent live-attenuated chimeric vaccines, Dengvaxia (Sanofi Pasteur) and TAK-003 (Takeda), will allow local manufacturers to dominate their respective domestic markets. In addition, the Butantan Institute is expected to export TetraVax-DV to other endemic Latin American markets from Q2 2019, greatly reducing the commercial attractiveness of this region for other vaccines companies. Aside from dengue-endemic markets, TetraVax-DV’s impressive immunogenicity in flavivirus-naïve recipients and its attractive dosing schedule also position it as a strong candidate for travelers and/or the military.

Table of Contents

Product Profiles
TetraVax-DV: Dengue vaccines

List of Figures
Figure 1: Design of the TetraVax-DV vaccine
Figure 2: TetraVax-DV for dengue fever - SWOT analysis

List of Tables
Table 1: TetraVax-DV drug profile
Table 2: TetraVax-DV completed studies in dengue fever
Table 3: TetraVax-DV ongoing studies in dengue fever